CSIMarket
 


Longeveron Inc   (LGVN)
Other Ticker:  
 

Longeveron Inc 's Leverage Ratio

LGVN's quarterly Leverage Ratio and Total Liabilities, Equity growth




LGVN Leverage Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity Change 10.22 % 19.19 % - - -
Y / Y Total Liabilities Change 33.18 % 23.12 % - - -
Leverage Ratio MRQ 0.24 0.2 0.14 0.13 0.2
Overall Ranking # # # # #
Seq. Equity Change -16.22 % -14.36 % -8.4 % 67.7 % -9.4 %
Seq. Total Liabilities Change -0.74 % 22.13 % 1.91 % 7.81 % -8.24 %



Leverage Ratio third quarter 2022 Comment
In Spite of the repayements of liabilities of -0.74%, in III. Quarter ,Leverage Ratio detoriated to 0.24, above company's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry Longeveron Inc achieved lowest Leverage Ratio. While total ranking remained unchanged compare to previous quarter at no. .

Explain Leverage Ratio?
Who are LGVN Customers?
Leverage Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Leverage Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Longeveron Inc 's Equity $ 25 Millions Visit LGVN's Balance sheet
Longeveron Inc 's Total Liabilities $ 6 Millions Visit LGVN's Balance sheet
Source of LGVN's Sales Visit LGVN's Sales by Geography


Cumulative Longeveron Inc 's Leverage Ratio

LGVN's Leverage Ratio for the trailling 12 Months

LGVN Leverage Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity TTM Growth 10.22 % 19.19 % - - -
Y / Y Total Liabilities TTM Growth 33.18 % 23.12 % - - -
Leverage Ratio TTM 0.17 0.16 0.16 0.17 0.2
Total Ranking TTM # 359 # 421 # 445 # 316 # 441
Seq. Equity TTM Growth -16.22 % -14.36 % -8.4 % 67.7 % -9.4 %
Seq. Total Liabilities TTM Growth -0.74 % 22.13 % 1.91 % 7.81 % -8.24 %


TTM Leverage Ratio Comment
On the trailing twelve months basis Despite of the repayements of liabilities of -0.74% in III. Quarter, Leverage Ratio improved to 0.17, a new company low.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 135 other companies have achieved lower Leverage Ratio than Longeveron Inc . While total ranking remained unchanged compare to previous quarter at no. 359.

Explain Leverage Ratio?
Who are LGVN Customers?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 136
Healthcare Sector # 219
Within the Market # 359


TTM Leverage Ratio Statistics
High Average Low
0.18 0.17 0.17
(Sep 30 2022)   (Dec 31 2021)




Companies with similar Leverage Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Leverage RatioSep 30 2022 MRQ Total LiabilitiesSep 30 2022 MRQ Equity
Revelation Biosciences Inc   0.66 $ 1.463  Millions$ 2.228  Millions
Igm Biosciences Inc   0.65 $ 212.761  Millions$ 328.175  Millions
Eagle Pharmaceuticals inc   0.65 $ 150.133  Millions$ 231.780  Millions
Abvc Biopharma Inc   0.65 $ 3.682  Millions$ 5.693  Millions
Actinium Pharmaceuticals Inc   0.64 $ 45.561  Millions$ 71.255  Millions
Novabay Pharmaceuticals Inc   0.62 $ 8.592  Millions$ 13.784  Millions
Organogenesis Holdings Inc   0.62 $ 157.963  Millions$ 256.328  Millions
Syros Pharmaceuticals Inc   0.61 $ 78.938  Millions$ 129.171  Millions
Vallon Pharmaceuticals Inc   0.61 $ 2.110  Millions$ 3.459  Millions
Nature s Sunshine Products inc   0.61 $ 85.766  Millions$ 141.754  Millions
Alpine Immune Sciences Inc   0.60 $ 109.590  Millions$ 182.009  Millions
Pds Biotechnology Corp  0.59 $ 27.828  Millions$ 47.059  Millions
Kiora Pharmaceuticals inc   0.59 $ 6.203  Millions$ 10.521  Millions
Applied Molecular Transport Inc   0.59 $ 46.212  Millions$ 78.395  Millions
Macrogenics Inc   0.59 $ 72.389  Millions$ 122.958  Millions
Acelrx Pharmaceuticals Inc  0.57 $ 15.432  Millions$ 27.226  Millions
Iterum Therapeutics Plc  0.56 $ 18.089  Millions$ 32.549  Millions
Marizyme Inc   0.55 $ 22.357  Millions$ 40.948  Millions
Medavail Holdings Inc   0.54 $ 16.807  Millions$ 31.306  Millions
Scpharmaceuticals Inc   0.53 $ 16.582  Millions$ 31.110  Millions
Vaxxinity Inc   0.53 $ 42.699  Millions$ 80.261  Millions
Aptinyx Inc   0.52 $ 25.193  Millions$ 48.792  Millions
Cyclerion Therapeutics Inc   0.52 $ 8.529  Millions$ 16.524  Millions
Aditxt Inc   0.51 $ 6.485  Millions$ 12.694  Millions
Cue Biopharma Inc   0.50 $ 25.536  Millions$ 50.764  Millions
Uniqure N v   0.50 $ 210.630  Millions$ 421.170  Millions
Cellectar Biosciences Inc   0.50 $ 6.367  Millions$ 12.751  Millions
Eyenovia inc   0.48 $ 9.692  Millions$ 20.329  Millions
Decibel Therapeutics Inc   0.47 $ 45.459  Millions$ 96.814  Millions
Metacrine Inc   0.46 $ 17.109  Millions$ 37.065  Millions

Date modified: 2022-11-16T07:45:10+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

PANA's Profile

Stock Price

PANA's Financials

Business Description

Fundamentals

Charts & Quotes

PANA's News

Suppliers

PANA's Competitors

Customers & Markets

Economic Indicators

PANA's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071